Oleyl-conjugated (WRH)4 peptides achieved 75% cellular uptake and 75% gene silencing in breast cancer cells, offering a new siRNA delivery approach.
75% gene silencingThe oleyl-(WRH)4 peptide silenced the cancer-promoting STAT3 gene by 75% in breast cancer cells
What the researchers found
Researchers synthesized oleyl-conjugated peptides of increasing length: oleyl-(WRH)1 through oleyl-(WRH)4. The peptide/siRNA complexes were non-cytotoxic at the working concentration (N/P ratio 40, about 20 μM) against breast cancer (MDA-MB-231, MCF-7), ovarian cancer (SK-OV-3), and normal (HEK-293) cells after 72 hours.
Oleyl-(WRH)3 and oleyl-(WRH)4 showed the best siRNA delivery: about 60% and 75% cellular uptake respectively in MDA-MB-231 and SK-OV-3 cells. The complexes formed particles under 200 nm in diameter and remained stable in serum at N/P ratios of 40 or above.
Western blot confirmed oleyl-(WRH)4 silenced the STAT3 gene by approximately 75% in MDA-MB-231 breast cancer cells and 45% in SK-OV-3 ovarian cancer cells.
Why it matters
Gene silencing with siRNA is a powerful approach to cancer treatment, but getting siRNA into cancer cells is the main bottleneck. Most delivery systems use lipid nanoparticles, which have limitations. Peptide-based delivery offers potential advantages in targeting, biocompatibility, and simplicity. This study shows that simple oleyl-peptide conjugates can deliver functional siRNA.
The numbers in context
- oleyl-(WRH)4: 75% cellular uptake in MDA-MB-231 cells
- oleyl-(WRH)4: 75% STAT3 gene silencing in MDA-MB-231
- oleyl-(WRH)4: 45% STAT3 gene silencing in SK-OV-3
- Non-cytotoxic at N/P 40 (~20 μM)
- Serum stable at N/P ≥ 40
- Particle diameter: <200 nm
How the study worked
Peptides were synthesized using Fmoc/tBu solid-phase chemistry, purified by HPLC, and characterized. Oleyl groups were conjugated to the peptide N-terminus. Peptide/siRNA complexes were formed at various N/P ratios. Cytotoxicity, serum stability, particle size, cellular uptake (fluorescence), and gene silencing (Western blot for STAT3) were measured in multiple cell lines.
Who was studied
In vitro study using breast cancer, ovarian cancer, and normal human kidney cell lines
What this study cannot tell us
This was tested in cell culture only, not in animals or humans. In vitro delivery does not predict in vivo performance, where the siRNA/peptide complex must survive the bloodstream, reach the tumor, and enter cells in a living organism. The study tested only one target gene (STAT3). Serum stability was assessed in vitro, not in circulating blood. The oleyl group may affect biodistribution and clearance in vivo.
How to read the evidence
Rated preliminary: in vitro study in cancer cell lines. In vivo delivery faces many additional challenges.
When this study was published
Published in 2024. Part of the growing field of peptide-based siRNA delivery systems.
The bigger picture
Gene silencing with siRNA is powerful but getting siRNA into cancer cells is the bottleneck. These lipid-modified peptides offer a simpler alternative to complex lipid nanoparticle systems.
Questions still open
- Will these peptides work in tumors inside living organisms?
- Can other cancer-relevant genes be silenced with this system?
Common questions
How do peptides deliver siRNA into cells?
What is STAT3 and why silence it?
Read the original research
Design, Synthesis, and Evaluation of Oleyl-WRH Peptides for siRNA Delivery.
Pharmaceuticals (Basel, Switzerland), 17(8)
Citation
Rai, Mrigank Shekhar; Sajid, Muhammad Imran; Moreno, Jonathan; Parang, Keykavous; Tiwari, Rakesh Kumar. (2024). Design, Synthesis, and Evaluation of Oleyl-WRH Peptides for siRNA Delivery.. Pharmaceuticals (Basel, Switzerland), 17(8). https://doi.org/10.3390/ph17081083